|
MX3864E
(es)
*
|
1975-05-27 |
1981-08-26 |
Syntex Corp |
Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
|
|
US4933168A
(en)
*
|
1975-05-27 |
1990-06-12 |
Syntex Pharmaceuticals International Limited |
Stable, crystalline flunisolide
|
|
GB1571629A
(en)
*
|
1977-11-30 |
1980-07-16 |
Fisons Ltd |
Pharmaceutical compositions containing beclomethasone dipropionate
|
|
IT1121513B
(it)
*
|
1979-05-28 |
1986-04-02 |
Chiesi Farma Spa |
Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
|
|
EP0039369B1
(fr)
*
|
1980-05-02 |
1983-06-15 |
Schering Corporation |
Solvats d'esters de béclométhasone, procédé pour leur préparation et préparation d'une formulation
|
|
FI63672C
(fi)
*
|
1980-05-19 |
1983-08-10 |
Orion Yhtymae Oy |
Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
|
|
KR890000664B1
(ko)
*
|
1981-10-19 |
1989-03-22 |
바리 안소니 뉴우샘 |
미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
|
|
GB8432063D0
(en)
*
|
1984-12-19 |
1985-01-30 |
Riker Laboratories Inc |
Physically modified steroids
|
|
US5962490A
(en)
*
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5562608A
(en)
*
|
1989-08-28 |
1996-10-08 |
Biopulmonics, Inc. |
Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
|
|
US5736509A
(en)
*
|
1990-12-14 |
1998-04-07 |
Texas Biotechnology Corporation |
Cyclic peptide surface feature mimics of endothelin
|
|
US5744123A
(en)
*
|
1991-12-12 |
1998-04-28 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
|
US5674471A
(en)
*
|
1991-12-12 |
1997-10-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and salbutamol
|
|
US5916540A
(en)
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
|
US5736124A
(en)
*
|
1991-12-12 |
1998-04-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicament
|
|
ATE171865T1
(de)
|
1991-12-12 |
1998-10-15 |
Glaxo Group Ltd |
Arzneimittel
|
|
IL104068A
(en)
|
1991-12-12 |
1998-10-30 |
Glaxo Group Ltd |
Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
|
|
US5658549A
(en)
*
|
1991-12-12 |
1997-08-19 |
Glaxo Group Limited |
Aerosol formulations containing propellant 134a and fluticasone propionate
|
|
US5653962A
(en)
*
|
1991-12-12 |
1997-08-05 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
|
US7105152B1
(en)
|
1991-12-18 |
2006-09-12 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
|
US5301664A
(en)
*
|
1992-03-06 |
1994-04-12 |
Sievers Robert E |
Methods and apparatus for drug delivery using supercritical solutions
|
|
DE69332240T2
(de)
*
|
1992-06-12 |
2003-04-10 |
Teijin Ltd., Osaka |
Ultrafeines pulver zur inhalation und dessen herstellung
|
|
MX9304585A
(es)
|
1992-07-31 |
1994-03-31 |
Glaxo Group Ltd |
Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
|
|
CA2159498A1
(fr)
*
|
1993-04-01 |
1994-10-13 |
Younsik Cha |
Methode de preparation de medicaments pour traiter les troubles dermiques
|
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6030991A
(en)
*
|
1993-05-20 |
2000-02-29 |
Texas Biotechnology Corp. |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
|
AU693590B2
(en)
*
|
1994-08-09 |
1998-07-02 |
Schering Corporation |
Process for preparing beclomethasone dipropionate freon (R) clathrate
|
|
US5983956A
(en)
*
|
1994-10-03 |
1999-11-16 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5980949A
(en)
*
|
1994-10-03 |
1999-11-09 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5863902A
(en)
*
|
1995-01-06 |
1999-01-26 |
Sibia Neurosciences, Inc. |
Methods of treating neurodegenerative disorders using protease inhibitors
|
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
|
US5646130A
(en)
*
|
1995-06-30 |
1997-07-08 |
Ocean University Of Oingdao |
Low molecular weight sulfated polysaccharides and uses thereof
|
|
US5977117A
(en)
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
|
US5700487A
(en)
*
|
1996-03-04 |
1997-12-23 |
The Ohio State University |
Treatment of pulmonary inflammation
|
|
US5958905A
(en)
*
|
1996-03-26 |
1999-09-28 |
Texas Biotechnology Corporation |
Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
|
|
US5804585A
(en)
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
|
EP0935415B1
(fr)
*
|
1996-05-01 |
2006-11-22 |
Imarx Pharmaceutical Corp. |
Procedes d'apport d'acides nucleiques dans une cellule in vitro
|
|
US6416960B1
(en)
|
1996-08-08 |
2002-07-09 |
Prolume, Ltd. |
Detection and visualization of neoplastic tissues and other tissues
|
|
US6599927B2
(en)
|
1996-10-11 |
2003-07-29 |
Astrazeneca Ab |
Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
|
|
SE9603725D0
(sv)
*
|
1996-10-11 |
1996-10-11 |
Astra Ab |
New teatment
|
|
US6458547B1
(en)
|
1996-12-12 |
2002-10-01 |
Prolume, Ltd. |
Apparatus and method for detecting and identifying infectious agents
|
|
SE9700135D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
SE9700133D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
|
SG100767A1
(en)
|
1997-04-28 |
2003-12-26 |
Texas Biotechnology Corp |
Sulfonamides for treatment of endothelin-mediated disorders
|
|
US6342611B1
(en)
*
|
1997-10-10 |
2002-01-29 |
Cytovia, Inc. |
Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
|
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
|
US6537813B1
(en)
|
1998-02-13 |
2003-03-25 |
Selective Genetics, Inc. |
Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
|
|
EP1925320A3
(fr)
|
1998-03-27 |
2008-09-03 |
Prolume, Ltd. |
Luciférases, protéines fluorescentes, acides nucléiques codant pour les luciférases et protéines fluorescentes et leur utilisation pour le diagnostic, le criblage à haut rendement et articles nouveaux
|
|
EP1100520B1
(fr)
*
|
1998-07-21 |
2004-09-22 |
Cytovia, Inc. |
Nouveaux colorants fluorescents et leurs applications dans des methodes de criblage par fluorescence de cellules entieres pour des caspases, peptidases, proteases et autres enzymes ainsi que leurs procedes d' utilisation
|
|
US6667299B1
(en)
*
|
2000-03-16 |
2003-12-23 |
Hollis-Eden Pharmaceuticals, Inc. |
Pharmaceutical compositions and treatment methods
|
|
WO2001036351A2
(fr)
|
1999-11-19 |
2001-05-25 |
Corvas International, Inc. |
Antagonistes de l'inhibiteur des activateurs du plasminogène
|
|
US6638977B1
(en)
|
1999-11-19 |
2003-10-28 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists
|
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
MXPA02006461A
(es)
|
1999-12-31 |
2003-09-05 |
Texas Biotechnology Corp |
Sulfonamidas y derivados de las mismas que modulan la actividad de endotelina.
|
|
US7109315B2
(en)
|
2000-03-15 |
2006-09-19 |
Bruce J. Bryan |
Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
|
|
US6596262B2
(en)
|
2001-02-15 |
2003-07-22 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6485707B2
(en)
|
2001-02-15 |
2002-11-26 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6544497B2
(en)
|
2001-02-15 |
2003-04-08 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
|
US20030129203A1
(en)
*
|
2001-08-27 |
2003-07-10 |
Nautilus Biotech S.A. |
Mutant recombinant adeno-associated viruses
|
|
CA2463724A1
(fr)
*
|
2001-10-16 |
2003-04-24 |
Structural Bioinformatics Inc. |
Organosulfures inhibiteurs de tyrosine phosphatases
|
|
AUPR868201A0
(en)
*
|
2001-11-05 |
2001-11-29 |
Thorlock International Limited |
Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
|
|
ATE521599T1
(de)
*
|
2001-12-21 |
2011-09-15 |
X Ceptor Therapeutics Inc |
Heterocyclische modulatoren von nukleären rezeptoren
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
WO2003059884A1
(fr)
|
2001-12-21 |
2003-07-24 |
X-Ceptor Therapeutics, Inc. |
Modulateurs de lxr
|
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
|
US20030199594A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Rasik Shah |
Helium propellant composition for use with aerosols
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
EP1517684B1
(fr)
|
2002-06-27 |
2009-07-22 |
Health Research, Inc. |
Photosensibilisants fluores associes a des chlores et des bacteriochlores pour la therapie photodynamique
|
|
US7053210B2
(en)
|
2002-07-02 |
2006-05-30 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its derivatives
|
|
US20060020396A1
(en)
*
|
2002-09-09 |
2006-01-26 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US20050202438A1
(en)
*
|
2002-09-09 |
2005-09-15 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
WO2004022593A2
(fr)
*
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Evolution rationnelle de cytokines pour une plus grande stabilite, les cytokines et molecules d'acide nucleique codant
|
|
BR0316397A
(pt)
*
|
2002-11-19 |
2005-09-27 |
Achillion Pharmaceuticals Inc |
Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral
|
|
AU2003293361A1
(en)
*
|
2002-12-18 |
2004-07-29 |
Glaxo Group Limited |
Drug delivery system with vented mouthpiece
|
|
CN1942588B
(zh)
|
2003-03-05 |
2013-06-12 |
海洋酶公司 |
可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
BRPI0410348A
(pt)
*
|
2003-05-14 |
2006-05-30 |
Torreypines Therapeutics Inc |
compostos e usos dos mesmos na modulação de amilóide-beta
|
|
MXPA05013075A
(es)
*
|
2003-06-03 |
2006-03-17 |
Novartis Ag |
Inhibidores de p-38 basados en heterociclo de 5 miembros.
|
|
EP1911754B1
(fr)
|
2003-08-13 |
2013-10-09 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de peptidase dipeptidyl
|
|
US7420000B2
(en)
|
2003-09-10 |
2008-09-02 |
University Of Southern California |
Amino phosphonate and amino bis-phosphonate derivatives
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
WO2005090370A1
(fr)
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Agents pharmacologiquement actifs contenant des phosphonates esterifies, et leurs procedes d'utilisation
|
|
US8519158B2
(en)
*
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
AU2005245470A1
(en)
|
2004-05-20 |
2005-12-01 |
Foldrx Pharmaceuticals, Inc. |
2-((hetero) aryl)-benzoxazole compounds and derivatives, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
|
|
US20060135773A1
(en)
*
|
2004-06-17 |
2006-06-22 |
Semple Joseph E |
Trisubstituted nitrogen modulators of tyrosine phosphatases
|
|
WO2006017124A2
(fr)
*
|
2004-07-09 |
2006-02-16 |
Cengent Therapeutics, Inc. |
Inhibiteurs de tyrosine phosphatases a heterocycle oxygene/azote
|
|
MX2007000490A
(es)
|
2004-07-12 |
2007-06-11 |
Idun Pharmaceuticals Inc |
Analogos de tetrapeptido.
|
|
EP1841749A1
(fr)
|
2004-09-02 |
2007-10-10 |
Metabasis Therapeutics, Inc. |
Derives d'inhibiteurs de thiazole et de thiadiazoles de tyrosine phosphatases
|
|
BRPI0515549A
(pt)
|
2004-09-17 |
2008-07-29 |
Whitehead Biomedical Inst |
compostos, composições e métodos de inibição de toxicidade de alfa-sinucleìna
|
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
|
EP1828192B1
(fr)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de dipeptidyle peptidase
|
|
EP1866319B1
(fr)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Nucleosides phosphono-pent-2-en-1-yle et analogues
|
|
CA2607806A1
(fr)
*
|
2005-05-04 |
2006-11-16 |
Nautilus Biotech, S.A. |
Polypeptides d'interferon-gamma modifies et procedes d'utilisation de polypeptides d'interferon-gamma modifies
|
|
CA2598216C
(fr)
*
|
2005-06-17 |
2014-04-08 |
Ligand Pharmaceuticals Incorporated |
Composes modulateurs du recepteur des androgenes et procedes associes
|
|
WO2007002109A2
(fr)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Chelateurs multicoordinants derives de pyrone destines a l'imagerie medicale et a la chelation
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
CA2626356C
(fr)
*
|
2005-10-21 |
2017-08-22 |
Catalyst Biosciences, Inc. |
Proteases modifiees qui inhibent l'activation du complement
|
|
WO2007076160A2
(fr)
*
|
2005-12-28 |
2007-07-05 |
Acidophil Llc |
Carbamates c-10 de taxanes
|
|
WO2007106537A2
(fr)
|
2006-03-13 |
2007-09-20 |
Activx Biosciences, Inc. |
Aminoquinolones utilisées comme inhibiteurs de la gsk-3
|
|
US20080038224A1
(en)
*
|
2006-03-28 |
2008-02-14 |
Thierry Guyon |
Modified interferon-beta (IFN-beta) polypeptides
|
|
WO2007126841A2
(fr)
*
|
2006-03-29 |
2007-11-08 |
Foldrx Pharmaceuticals, Inc. |
Inhibition de la toxicité de l'alpha-synucléine
|
|
US20070286814A1
(en)
*
|
2006-06-12 |
2007-12-13 |
Medispray Laboratories Pvt. Ltd. |
Stable aerosol pharmaceutical formulations
|
|
WO2007149406A2
(fr)
|
2006-06-19 |
2007-12-27 |
Nautilus Technology Llc |
Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
|
|
MX2009002151A
(es)
|
2006-08-28 |
2009-07-03 |
Kirin Pharma Kk |
Anticuerpos monoclonales humanos especificos para light humano antagonistas.
|
|
US7879846B2
(en)
|
2006-09-21 |
2011-02-01 |
Kyorin Pharmaceutical Co.., Ltd. |
Serine hydrolase inhibitors
|
|
EP2145878A3
(fr)
|
2006-10-09 |
2010-02-24 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de kinases Aurora
|
|
JP2010505961A
(ja)
|
2006-10-09 |
2010-02-25 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
|
EP2089359A2
(fr)
|
2006-10-31 |
2009-08-19 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de kinase mapk/erk
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
WO2009070164A1
(fr)
|
2007-11-28 |
2009-06-04 |
University Of Central Florida |
Amélioration de la vigueur par administration de dérivés de pyrimidine
|
|
WO2008065372A2
(fr)
|
2006-11-28 |
2008-06-05 |
Nautilus Biotech, S.A. |
Polypeptides d'érythropoïétine modifiés et utilisation de ceux-ci dans des traitements
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
CN101611008A
(zh)
*
|
2006-12-22 |
2009-12-23 |
恩希赛弗制药公司 |
C3a受体调节剂及其使用方法
|
|
EP2425820B1
(fr)
|
2007-02-11 |
2015-04-08 |
MAP Pharmaceuticals Inc |
Procédé pour l'administration thérapeutique de DHE pour soulager rapidement la migraine tout en diminuant son profil d'effets secondaires
|
|
ATE525068T1
(de)
|
2007-02-28 |
2011-10-15 |
Conatus Pharmaceuticals Inc |
Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
|
|
MX2010002667A
(es)
*
|
2007-09-11 |
2010-04-01 |
Activx Biosciences Inc |
Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
|
|
WO2009035684A1
(fr)
|
2007-09-12 |
2009-03-19 |
Activx Biosciences, Inc. |
Aminoquinolones spirocycliques utilisées en tant qu'inhibiteurs de gsk-3
|
|
EP2564850B1
(fr)
|
2007-09-25 |
2014-08-13 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de kinase de type polo
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
AU2008327615B2
(en)
*
|
2007-11-21 |
2014-08-21 |
Pharmaxis Ltd. |
Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
|
|
PL2222636T3
(pl)
|
2007-12-21 |
2014-04-30 |
Ligand Pharm Inc |
Selektywne modulatory receptorów androgenowych (SARM) i ich zastosowania
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
CA2721229C
(fr)
|
2008-04-14 |
2022-08-23 |
Halozyme, Inc. |
Hyaluronidases modifiees et utilisations pour traiter des maladies et des pathologies associees a l'acide hyaluronique
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
JP2011525535A
(ja)
|
2008-06-24 |
2011-09-22 |
武田薬品工業株式会社 |
ＰＩ３Ｋ／ｍＴＯＲ阻害剤
|
|
EP2318035B1
(fr)
|
2008-07-01 |
2019-06-12 |
Curemark, Llc |
Procédés et compositions pour le traitement de symptômes de troubles de santé neurologiques et mentaux
|
|
KR101493644B1
(ko)
|
2008-12-09 |
2015-02-13 |
할로자임, 아이엔씨 |
연장된 가용성 ｐｈ20 폴리펩티드 및 그의 용도
|
|
CN105664144B
(zh)
|
2009-01-06 |
2020-08-11 |
加尔纳根有限责任公司 |
治疗或预防金黄色葡萄球菌感染以及根除或减少表面上金黄色葡萄球菌的组合物和方法
|
|
KR101694931B1
(ko)
|
2009-01-06 |
2017-01-10 |
큐어론 엘엘씨 |
이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
|
|
JP5649589B2
(ja)
|
2009-03-06 |
2015-01-07 |
ハロザイム インコーポレイテッド |
マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用
|
|
BRPI1008974A2
(pt)
*
|
2009-03-11 |
2017-06-06 |
Kyorin Seiyaku Kk |
composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
|
|
EP2415767B1
(fr)
|
2009-03-27 |
2014-09-03 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la poly(ADP-ribose)polymérase (PARP)
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
JP5715625B2
(ja)
|
2009-07-30 |
2015-05-07 |
武田薬品工業株式会社 |
ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
|
|
WO2011041293A1
(fr)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Dérivés pyrazolo [1, 5a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
|
|
US8871460B2
(en)
|
2009-11-09 |
2014-10-28 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
|
EP2521721B1
(fr)
*
|
2009-12-30 |
2014-10-01 |
Shanghai Fochon Pharmaceutical Co. Ltd |
Dérivés de 3-(3-aminopipéridin-1-yl)-5-oxo-1,2,4-triazine à titre d'inhibiteurs de dipeptidyl peptidase iv (dpp-iv)
|
|
CN102834393B
(zh)
|
2010-02-03 |
2015-07-22 |
武田药品工业株式会社 |
细胞凋亡信号调节激酶1抑制剂
|
|
EP2585455B1
(fr)
|
2010-06-24 |
2019-08-07 |
The Regents of the University of California |
Composés et leurs utilisations dans la modulation des niveaux de différentes alloformes du peptide amyloïde bêta
|
|
WO2012145651A2
(fr)
|
2011-04-21 |
2012-10-26 |
Curemark, Llc |
Composés destinés au traitement de troubles neuropsychiatriques
|
|
JP2014517076A
(ja)
|
2011-06-23 |
2014-07-17 |
マップ・ファーマシューティカルズ・インコーポレイテッド |
新規のフルオロエルゴリン類似体
|
|
WO2013037482A1
(fr)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Agonistes du récepteur du farnésoïde x pour le traitement et la prévention du cancer
|
|
SG11201403434YA
(en)
|
2011-12-19 |
2014-09-26 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
|
US8946420B2
(en)
|
2011-12-21 |
2015-02-03 |
Map Pharmaceuticals, Inc. |
Neuromodulatory compounds
|
|
EP3130347B1
(fr)
|
2011-12-30 |
2019-09-18 |
Halozyme, Inc. |
Variants polypeptidiques ph20, formulations et utilisations de ceux-ci
|
|
EP3971178A1
(fr)
|
2012-03-07 |
2022-03-23 |
The McLean Hospital Corporation |
Dérivés d'aminoquinoléine et leurs utilisations
|
|
KR101809858B1
(ko)
|
2012-04-04 |
2017-12-15 |
할로자임, 아이엔씨 |
항-히알루로난 제제 및 종양-표적 탁산을 이용한 병용 치료
|
|
BR112014027406B1
(pt)
|
2012-05-02 |
2020-09-24 |
Boehringer Ingelheim International Gmbh |
Composto, composição e uso de um composto
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
US9732038B2
(en)
|
2012-06-14 |
2017-08-15 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of STAT3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
JP2016503795A
(ja)
|
2012-12-21 |
2016-02-08 |
マップ ファーマシューティカルズ インコーポレイテッド |
新規メチセルジド誘導体
|
|
US20150196625A9
(en)
|
2013-01-07 |
2015-07-16 |
Rudolph D. Paladini |
Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
|
|
CA2902232C
(fr)
|
2013-02-22 |
2020-12-29 |
University Of Southern California |
Methodes de traitement de maladies et de troubles ophtalmiques
|
|
WO2014165263A1
(fr)
|
2013-03-12 |
2014-10-09 |
The Regents Of The University Of California, A California Corporation |
Modulateurs de gamma-secrétase
|
|
EP3935944A1
(fr)
|
2013-03-15 |
2022-01-12 |
University Of Southern California, USC Stevens |
Composés pour le traitement des maladies musculo-squelettiques
|
|
NZ714765A
(en)
|
2013-06-06 |
2021-12-24 |
Pf Medicament |
Anti-c10orf54 antibodies and uses thereof
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
US10441567B2
(en)
|
2014-01-17 |
2019-10-15 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
SG11201609256SA
(en)
|
2014-05-12 |
2016-12-29 |
Conatus Pharmaceuticals Inc |
Treatment of the complications of chronic liver disease with caspase inhibitors
|
|
SG11201609721WA
(en)
|
2014-05-28 |
2016-12-29 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
DK3207130T3
(da)
|
2014-10-14 |
2019-11-11 |
Halozyme Inc |
Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
|
|
WO2016065264A1
(fr)
|
2014-10-24 |
2016-04-28 |
Biogen Ma Inc. |
Dérivés de diterpénoïdes et leurs procédés d'utilisation
|
|
JP6672296B2
(ja)
|
2014-10-31 |
2020-03-25 |
ザ ジェネラル ホスピタル コーポレイション |
強力なγ−セクレターゼモジュレータ
|
|
BR112017012344B1
(pt)
|
2014-12-11 |
2024-02-06 |
Pierre Fabre Medicament |
Anticorpo anti-c10orf54 ou fragmento de ligação ao antígeno do mesmo, conjugado anticorpo-fármaco, composição farmacêutica, kit, seus usos, polinucleotídeo, vetor de expressão e métodos de produção do anticorpo ou fragmento de ligação ao antígeno e de detecção c10orf54 em uma amostra
|
|
EP3789039A1
(fr)
|
2014-12-22 |
2021-03-10 |
The Rockefeller University |
Anticorps agonistes anti-mertk et leurs utilisations
|
|
MX2017009406A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo isoergolina y usos de estos.
|
|
WO2016118541A1
(fr)
|
2015-01-20 |
2016-07-28 |
Xoc Pharmaceuticals, Inc |
Composés d'ergoline et leurs utilisations
|
|
PT3265123T
(pt)
|
2015-03-03 |
2023-02-01 |
Kymab Ltd |
Anticorpos, usos e métodos
|
|
WO2016176617A2
(fr)
|
2015-04-29 |
2016-11-03 |
New York University |
Procédé pour le traitement de gliomes de haut grade
|
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
RS62709B1
(sr)
|
2015-08-17 |
2022-01-31 |
Kura Oncology Inc |
Postupci za lečenje pacijenata obolelih od kancera pomoću inhibitora farneziltransferaze
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
WO2017079566A1
(fr)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
JP7011596B2
(ja)
|
2015-12-02 |
2022-02-10 |
アストライア セラピューティクス， エルエルシー |
ピペリジニルノシセプチン受容体化合物
|
|
US20190022043A1
(en)
|
2015-12-31 |
2019-01-24 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
|
CA3010801A1
(fr)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Methodes de traitement du cancer et utilisation de biomarqueurs en tant que facteurs predictifs de la sensibilite clinique a des traitements
|
|
LT3399978T
(lt)
|
2016-01-08 |
2021-05-10 |
Celgene Corporation |
Antiproliferaciniai junginiai, jų farmacinės kompozicijos ir naudojimas
|
|
ES2959267T3
(es)
|
2016-01-08 |
2024-02-22 |
Celgene Corp |
Formas sólidas de 2-(4-clorofenil)-n-((2-2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos
|
|
WO2017151836A1
(fr)
|
2016-03-04 |
2017-09-08 |
East Carolina University |
Prostaglandine-éthanolamides de série j utilisés comme nouveaux agents thérapeutiques pour des troubles de la peau et/ou bucco-dentaires
|
|
US10064855B2
(en)
|
2016-03-08 |
2018-09-04 |
Los Gatos Pharmaceuticals, Inc. |
Composite nanoparticles and uses thereof
|
|
EP3426352A4
(fr)
|
2016-03-08 |
2019-11-13 |
Los Gatos Pharmaceuticals, Inc. |
Dérivés de camptothécine et leurs utilisations
|
|
WO2017180794A1
(fr)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Acides hydroxamiques de bêta-lactame o-sulfatés deutérés et bêta-lactames n-sulfatés deutérés
|
|
US20190119758A1
(en)
|
2016-04-22 |
2019-04-25 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
ES2939373T3
(es)
|
2016-05-13 |
2023-04-21 |
Pasteur Institut |
Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
|
|
WO2017205721A1
(fr)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anticorps anti-tim-3 et leurs méthodes d'utilisation
|
|
MA45602A
(fr)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
|
WO2018035281A1
(fr)
|
2016-08-17 |
2018-02-22 |
North Carolina State University |
Voie nord-sud pour la synthèse de bactériochlorines
|
|
BR112019007369A2
(pt)
|
2016-10-11 |
2019-07-16 |
Agenus Inc |
anticorpos anti-lag-3 e métodos de uso dos mesmos
|
|
EP3534947A1
(fr)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
|
|
PL3534885T3
(pl)
|
2016-11-03 |
2021-11-15 |
Kura Oncology, Inc. |
Inhibitory farnezylotransferazy do zastosowania w leczeniu nowotworu
|
|
KR102431830B1
(ko)
|
2016-11-07 |
2022-08-16 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
|
WO2018089692A1
(fr)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Dérivés d'eckol, procédés de synthèse et utilisations associées
|
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
IL307242A
(en)
|
2016-12-07 |
2023-11-01 |
Agenus Inc |
Anti-CTLA-4 antibodies and methods of using them
|
|
EP3551225A1
(fr)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Anticorps et procédés d'utilisation de ceux-ci
|
|
WO2018156609A1
(fr)
|
2017-02-21 |
2018-08-30 |
Kura Oncology, Inc. |
Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
EP3609528A4
(fr)
|
2017-04-10 |
2020-12-23 |
Curemark, LLC |
Compositions pour le traitement de l'accoutumance
|
|
TW202500588A
(zh)
|
2017-04-13 |
2025-01-01 |
美商艾吉納斯公司 |
抗ｃｄ１３７抗體及其使用方法
|
|
JP2020517242A
(ja)
|
2017-04-21 |
2020-06-18 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ＡｐｏＣ３抗体およびその使用方法
|
|
TW202402800A
(zh)
|
2017-05-01 |
2024-01-16 |
美商艾吉納斯公司 |
抗ｔｉｇｉｔ抗體類和使用彼等之方法
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
CN111132980A
(zh)
|
2017-06-01 |
2020-05-08 |
Xoc制药股份有限公司 |
用于医学的麦角灵衍生物
|
|
AU2018290281B2
(en)
|
2017-06-22 |
2021-12-16 |
Vertex Pharmaceuticals Incorporated |
Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
|
|
EP3645029B1
(fr)
|
2017-06-26 |
2023-01-18 |
Institut Pasteur |
Traitements pour éliminer des réservoirs de vih et réduire la charge virale
|
|
EP3645563A4
(fr)
|
2017-06-27 |
2021-03-17 |
Neuracle Science Co., Ltd |
Anticorps anti-fam19a5 et leurs utilisations
|
|
KR102573257B1
(ko)
|
2017-06-27 |
2023-09-01 |
주식회사 뉴라클사이언스 |
섬유증의 치료를 위한 항-fam19a5 항체의 용도
|
|
WO2019003164A1
(fr)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
Utilisation d'anticorps anti-fam19a5 pour le traitement de cancers
|
|
KR102472683B1
(ko)
|
2017-06-27 |
2022-12-01 |
주식회사 뉴라클사이언스 |
녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
|
|
CA3069523A1
(fr)
|
2017-07-11 |
2019-01-17 |
Actym Therapeutics, Inc. |
Souches bacteriennes immunostimulatrices modifiees et utilisations
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2019032489A1
(fr)
|
2017-08-07 |
2019-02-14 |
Kura Oncology, Inc. |
Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
|
|
ES2953032T3
(es)
|
2017-09-01 |
2023-11-07 |
Univ East Carolina |
Métodos ex vivo para la activación de las células inmunológicas
|
|
US12072339B2
(en)
|
2017-10-02 |
2024-08-27 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment and diagnosis of mood disorders
|
|
JP7039694B2
(ja)
|
2017-10-31 |
2022-03-22 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ａｐｏｃ３抗体およびその使用方法
|
|
US20190216751A1
(en)
|
2017-11-15 |
2019-07-18 |
California State University Northridge |
Compositions and Methods for the Treatment and Prevention of Cancer
|
|
WO2019113269A1
(fr)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
|
|
AU2019259798A1
(en)
|
2018-04-24 |
2020-11-12 |
Neuracle Science Co., Ltd. |
Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
|
|
CN119662732A
(zh)
|
2018-05-08 |
2025-03-21 |
纽洛可科学有限公司 |
抗fam19a5抗体的腺相关病毒（aav）递送
|
|
AU2019265888A1
(en)
|
2018-05-10 |
2020-11-26 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
WO2020006341A1
(fr)
|
2018-06-29 |
2020-01-02 |
Conatus Pharmaceuticals, Inc. |
Dérivés d'acide (s)-3-(2-(4-(benzyl)-3-oxopipérazin-1-yl)acétamido)-4-oxo-5-(2,3,5,6-tétrafluorophénoxy)pentanoïque et composés apparentés utilisés en tant qu'inhibiteurs de caspase pour le traitement de maladies cardiovasculaires
|
|
CA3176812A1
(fr)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Souches bacteriennes immunostimulatrices modifiees et utilisations associees
|
|
CA3106418A1
(fr)
|
2018-07-20 |
2020-01-23 |
Pierre Fabre Medicament |
Recepteur pour vista
|
|
US11242528B2
(en)
|
2018-08-28 |
2022-02-08 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
|
CA3115797A1
(fr)
|
2018-10-16 |
2020-04-23 |
Neuracle Science Co., Ltd. |
Utilisation d'anticorps anti-fam19a5
|
|
WO2020092720A2
(fr)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
|
|
WO2020102728A1
(fr)
|
2018-11-16 |
2020-05-22 |
Neoimmunetech, Inc. |
Méthode de traitement d'une tumeur au moyen de l'association de la protéine il-7 et d'un inhibiteur de point de contrôle immunitaire
|
|
EP3898609A1
(fr)
|
2018-12-19 |
2021-10-27 |
Shy Therapeutics LLC |
Composés interagissant avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladie fibrotique
|
|
WO2020128033A1
(fr)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Métabolisme cellulaire de l'ensemencement d'un réservoir de vih-1 dans des lymphocytes t cd4+
|
|
KR20210106513A
(ko)
|
2018-12-21 |
2021-08-30 |
쿠라 온콜로지, 인크. |
편평 세포 암종을 위한 요법
|
|
US12247070B2
(en)
|
2018-12-27 |
2025-03-11 |
Neuracle Science Co., Ltd. |
Use of anti-FAM19A5 antibodies for treating atherosclerosis
|
|
PH12021551405A1
(en)
|
2018-12-28 |
2022-05-11 |
Vertex Pharma |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
SG11202104217QA
(en)
|
2019-01-02 |
2021-05-28 |
Neuracle Science Co Ltd |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
US11447468B2
(en)
|
2019-02-06 |
2022-09-20 |
Dice Alpha, Inc. |
IL-17 ligands and uses thereof
|
|
CA3130303A1
(fr)
|
2019-02-26 |
2020-09-03 |
Rgenix, Inc. |
Anticorps anti-mertk a affinite elevee et utilisations associees
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
CN113748124A
(zh)
|
2019-02-27 |
2021-12-03 |
阿克蒂姆治疗有限公司 |
工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌
|
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
CA3132613A1
(fr)
|
2019-03-07 |
2020-09-10 |
Conatus Pharmaceuticals Inc. |
Inhibiteurs de caspase et leurs procedes d'utilisation
|
|
TW202108170A
(zh)
|
2019-03-15 |
2021-03-01 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
|
|
KR20210144778A
(ko)
|
2019-03-29 |
2021-11-30 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용한 편평 세포 암종의 치료 방법
|
|
TW202102218A
(zh)
|
2019-04-01 |
2021-01-16 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
|
|
AU2020257397A1
(en)
|
2019-04-19 |
2021-12-16 |
Ligand Pharmaceuticals Inc. |
Crystalline forms and methods of producing crystalline forms of a compound
|
|
WO2020223583A1
(fr)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Méthodes de traitement de la leucémie myéloïde aiguë avec des inhibiteurs de la farnésyltransférase
|
|
JP2022532925A
(ja)
|
2019-05-20 |
2022-07-20 |
ニルバナ サイエンシーズ インク． |
発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
|
|
WO2020236818A1
(fr)
|
2019-05-20 |
2020-11-26 |
Nirvana Sciences Inc. |
Colorants à émission étroite, compositions contenant ces derniers, et méthodes de production et d'utilisation correspondantes
|
|
PE20221151A1
(es)
|
2019-08-30 |
2022-07-18 |
Agenus Inc |
Anticuerpos anti-cd96 y sus metodos de uso
|
|
IL291345B2
(en)
|
2019-09-16 |
2024-04-01 |
Dice Alpha Inc |
Il-17a modulators and uses thereof
|
|
AU2020382614B2
(en)
|
2019-11-12 |
2025-12-11 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
|
|
WO2021146191A1
(fr)
|
2020-01-13 |
2021-07-22 |
Neoimmunetech, Inc. |
Procédé de traitement d'une tumeur au moyen d'une combinaison d'une protéine il-7 et d'un anticorps bispécifique
|
|
EP4100045A1
(fr)
|
2020-02-05 |
2022-12-14 |
Washington University |
Procédé de traitement d'une tumeur solide avec une combinaison d'une protéine d'il-7 et de cellules immunitaires porteuses de car
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
US12024521B2
(en)
|
2020-06-30 |
2024-07-02 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
|
WO2022036159A2
(fr)
|
2020-08-12 |
2022-02-17 |
Actym Therapeutics, Inc. |
Vaccins à base de bactéries immunostimulatrices, agents thérapeutiques et plateformes d'administration d'arn
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
WO2022093718A1
(fr)
|
2020-10-26 |
2022-05-05 |
Neoimmunetech, Inc. |
Procédés d'induction de la mobilisation de cellules souches
|
|
WO2022094475A1
(fr)
|
2020-11-02 |
2022-05-05 |
Neoimmunetech, Inc. |
Utilisation de l'interleukine-7 pour le traitement du coronavirus
|
|
CN116615236A
(zh)
|
2020-11-05 |
2023-08-18 |
新免疫技术有限公司 |
用il-7蛋白和核苷酸疫苗的组合治疗肿瘤的方法
|
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
JP2024510196A
(ja)
|
2021-03-10 |
2024-03-06 |
ダイス・モレキュールズ・エスブイ・インコーポレイテッド |
アルファｖベータ６およびアルファｖベータ１インテグリン阻害剤およびその使用
|
|
WO2022226166A1
(fr)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Imidazolidinediones et imidazolidinones spirocycliques pour le traitement d'une amylose à chaîne légère
|
|
EP4347568A1
(fr)
|
2021-05-27 |
2024-04-10 |
Protego Biopharma, Inc. |
Hétéroaryl-diamides activateurs d'ire1/xbp1s
|
|
IL309349A
(en)
|
2021-06-14 |
2024-02-01 |
argenx BV |
Antibodies against interleukin 9 and methods of using them
|
|
US12017997B2
(en)
|
2021-10-22 |
2024-06-25 |
Prosetta Biosciences, Inc. |
Host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
CA3237696A1
(fr)
|
2021-11-08 |
2023-05-11 |
Progentos Therapeutics, Inc. |
Inhibiteurs du recepteur du facteur de croissance derive des plaquettes (pdgfr) alpha et leurs utilisations
|
|
EP4456907A1
(fr)
|
2021-12-30 |
2024-11-06 |
NeoImmuneTech, Inc. |
Procédé de traitement d'une tumeur avec une combinaison d'une protéine il-7 et d'un antagoniste du vegf
|
|
US11981694B2
(en)
|
2022-01-03 |
2024-05-14 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
WO2023129577A1
(fr)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Promédicaments à base de thiol cyclique
|
|
US12168673B2
(en)
|
2022-03-02 |
2024-12-17 |
Mitopower, Inc. |
Prodrugs derived from nicotinic acid and ribose
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
WO2023198757A1
(fr)
|
2022-04-14 |
2023-10-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Alpha-1-antitrypsine pour le traitement d'infections à paramyxoviridae ou orthomyxoviridae
|
|
JP2025513877A
(ja)
|
2022-04-14 |
2025-04-30 |
ブリストル－マイヤーズ スクイブ カンパニー |
新規なｇｓｐｔ１化合物およびその新規な化合物の使用方法
|
|
JP2025537484A
(ja)
|
2022-10-21 |
2025-11-18 |
ダイアゴナル・セラピューティクス・インコーポレイテッド |
Ｉｌ－１８受容体に対するヘテロマーアゴニスト抗体
|
|
US20240174672A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridone Compounds
|
|
WO2024092043A1
(fr)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Composés de pyridine contenant un spirocycle
|
|
EP4608839A1
(fr)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Composés hétéroaryle bicycliques contenant un spirocycle
|
|
EP4615485A1
(fr)
|
2022-11-07 |
2025-09-17 |
NeoImmuneTech, Inc. |
Procédés de traitement d'une tumeur avec un promoteur mgmt non méthylé
|
|
EP4626864A1
(fr)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Diamides hétéroaryles linéaires comme activateurs d'ire1/xbp1s
|
|
EP4626865A1
(fr)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Activateurs de ire1/xbp1 diamide de pyrazole cyclique
|
|
WO2024194685A2
(fr)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anticorps anti-phosphocholine et leurs procédés d'utilisation
|
|
EP4680632A2
(fr)
|
2023-03-17 |
2026-01-21 |
Oxitope Pharma B.V. |
Anticorps anti-phosphocholine et leurs procédés d'utilisation
|
|
CN121057752A
(zh)
|
2023-04-07 |
2025-12-02 |
达科纳治疗有限公司 |
铰链经修饰的双特异性抗体
|
|
CN121127500A
(zh)
|
2023-04-07 |
2025-12-12 |
达科纳治疗有限公司 |
针对激活素a受体样1型(alk1)的双特异性激动性抗体
|
|
WO2024226471A2
(fr)
|
2023-04-24 |
2024-10-31 |
Biomarin Pharmaceutical Inc. |
Compositions et méthodes de traitement de troubles liés à stxbp1
|
|
WO2024233642A1
(fr)
|
2023-05-09 |
2024-11-14 |
Progentos Therapeutics, Inc. |
Composés hétérocycliques et leurs utilisations
|
|
WO2024243048A1
(fr)
|
2023-05-19 |
2024-11-28 |
Diagonal Therapeutics Inc. |
Anticorps agonistes bispécifiques dirigés contre le récepteur d'il12
|
|
WO2025010272A1
(fr)
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Molécules fc hétérodimères et leurs utilisations
|
|
WO2025049818A1
(fr)
|
2023-08-29 |
2025-03-06 |
Enosi Therapeutics Corporation |
Antagonistes tnfr1 dépourvus d'activité agoniste et leurs utilisations
|
|
TW202515919A
(zh)
|
2023-09-01 |
2025-04-16 |
比利時商艾托斯比利時公司 |
抗ｔｒｅｍ２抗體及使用方法
|
|
WO2025063888A1
(fr)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Composés ciblant la survivine
|
|
US20250122182A1
(en)
|
2023-09-27 |
2025-04-17 |
Isosterix, Inc. |
MYST Inhibitors
|
|
WO2025085416A1
(fr)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Composés gspt1 et procédés d'utilisation des composés
|
|
WO2025090519A1
(fr)
|
2023-10-23 |
2025-05-01 |
Diagonal Therapeutics Inc. |
Anticorps agonistes hétéromériques dirigés contre le récepteur de l'il-18
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025133707A1
(fr)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anticorps anti-tdp-43 et leurs utilisations
|
|
WO2025147691A1
(fr)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions et procédés de dégradation de protéine de translocation nucléaire de récepteur d'hydrocarbure aryle
|
|
WO2025179161A1
(fr)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Composés de dégradation de protéines
|
|
WO2025201633A1
(fr)
|
2024-03-26 |
2025-10-02 |
Chen Gefei |
Agent pour réduire la formation d'amyloïdes
|
|
WO2025255341A1
(fr)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Activateurs de tétrahydrofuranyle ire1/xbp1s
|